News | August 10, 2022
Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Subscribe To Our Newsletter & Stay Updated
